The Post-Pandemic Tripledemic: Forecasting the burden of Influenza, RSV, and COVID-19

Posted on Jul 20, 2023

Airfinity’s next industry roundtable will see experts across respiratory diseases and pandemic preparedness come together to discuss Airfinity’s ‘tripledemic’ forecasts, vaccine and treatment demand, and the impact of new medical countermeasures on disease outcomes.

We’re also pleased to announce our first panellist as Anant Shah, Commercial New Products Lead, COVID and Respiratory Combo Vaccines at Moderna. Anant has over 20 years of experience in public health, infectious diseases, and vaccine development.

Join us online on Wednesday 6th September at 11am ET/4pm BST to learn more about the ongoing seasonal burden of influenza, RSV, and COVID19.

Register your free place here.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022